What is the clinical evidence from this study?

Study design: Review. Population: Transthyretin amyloid cardiomyopathy.

What question did this study set out to answer?

Provide updated clinical recommendations for the noninvasive evaluation, therapeutic selection, and ongoing management of transthyretin amyloid cardiomyopathy.

May 10, 2026Journal of the American College of Cardiology

Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance

View Full Paper

Ask AI

Bookmark

Why the study?

Transthyretin amyloid cardiomyopathy is an increasingly recognized cause of heart failure with advances in diagnosis and therapies requiring updated clinical guidance.

Key Points

Provide updated clinical recommendations for the noninvasive evaluation, therapeutic selection, and ongoing management of transthyretin amyloid cardiomyopathy.
Synthesized expert consensus guidance from the American College of Cardiology regarding evaluation pathways and clinical care standards.
Evaluated noninvasive diagnostic workflows involving radionuclide scintigraphy alongside specific disease-modifying and guideline-directed heart failure regimens.
Identified noninvasive radionuclide scintigraphy paired with negative monoclonal protein screens as an accurate diagnostic standard for transthyretin amyloid cardiomyopathy.
Highlighted therapeutic benefits achieved with transthyretin stabilizers (tafamidis and acoramidis), the transthyretin silencer vutrisiran, and broader heart failure therapies including SGLT2 inhibitors and mineralocorticoid receptor antagonists.

Structured PICO

Population

Individuals with transthyretin amyloid cardiomyopathy, particularly older individuals and those with musculoskeletal manifestations such as bilateral carpal tunnel syndrome or spinal stenosis

Intervention

Updated strategies for diagnosis (including radionuclide scintigraphy) and management (including mineralocorticoid receptor antagonists, sodium glucose-cotransporter 2 inhibitors, tafamidis, acoramidis, and vutrisiran)

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

The 2025 ACC Concise Clinical Guidance provides updated recommendations for the diagnosis and management of transthyretin amyloid cardiomyopathy, incorporating recent advances in noninvasive imaging and disease-modifying therapies.

Cite This Study

Kittleson et al. (2025) conducted a review in Transthyretin amyloid cardiomyopathy. This 2025 ACC Concise Clinical Guidance provides updated strategies for the diagnosis and management of transthyretin amyloid cardiomyopathy, focusing on disease-modifying and heart failure therapies.

synapsesocial.com/papers/69fff921af8a41e309dd2600 https://doi.org/10.1016/j.jacc.2025.09.004

View Full Paper

Ask AI

Bookmark

Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider